BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

MedImmune Lands $100 Million from AstraZeneca PLC (AZN), Invests in NeuProtect Pty Ltd


12/5/2011 8:34:59 AM

Washington Business Journal by Tucker Echols, Broadcast/Web Reporter

MedImmune Ventures, the venture capital arm of Gaithersburg-based MedImmune, has secured $100 million in funding from MedImmune's parent AstraZenca.

“We continue to support MedImmune Ventures' strategy that combines commitment to advance science and technology in the life science industry while generating financial returns expected of venture capital funds,” said AstraZeneca Chief Financial Officer Simon Lowth.

The capital raise brings MedImmune Ventures' total capital under management to $400 million.

MedImmune Ventures, which focuses on equity investments in private companies in the areas of biopharmaceuticals, medical and healthcare technology, has been active recently, co-leading the second round of financing for NeuProtect Pty Ltd, an Australian life science company specialised in the reduction of cardiac remodelling post myocardial infarction. The other co-leader in the round was Starfish Ventures.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->